Baylor College of Medicine: CAR-NKT Cell Therapy Shows Promising Results Against Neuroblastoma in Phase 1 Clinical Trial
May 16, 2023
May 16, 2023
HOUSTON, Texas, May 16 (TNSjou) -- The Baylor College of Medicine issued the following news:
Researchers at Baylor College of Medicine/Texas Children's Cancer Center and collaborating institutions report interim results from a first-in-human phase 1 clinical trial evaluating the safety, antitumor activity and immunological characteristics of a genetically engineered natural killer T (NKT) cell immunotherapy for neuroblastoma, a childhood tumor that most commonly arises in the adrena . . .
Researchers at Baylor College of Medicine/Texas Children's Cancer Center and collaborating institutions report interim results from a first-in-human phase 1 clinical trial evaluating the safety, antitumor activity and immunological characteristics of a genetically engineered natural killer T (NKT) cell immunotherapy for neuroblastoma, a childhood tumor that most commonly arises in the adrena . . .